Clinical characteristics and prognostic analysis of 22 cases of SMARCA4-deficient thoracic tumors: a retrospective observational study.

ABSTRACT:

Background

SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4) encodes the BRG1 (Brahma-related gene 1) protein, which regulates chromatin remodeling and gene expression; its loss leads to chromatin reorganization and aberrant expression of tumor-related genes, and it has been detected in multiple aggressive malignancies. SMARCA4-deficient thoracic tumors (SMARCA4-dTTs) mainly include the highly malignant SMARCA4-deficient undifferentiated tumor [SMARCA4-dUT, recognized as a distinct entity in the 2021 World Health Organization (WHO) classification] and SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC). Currently, there is no standard treatment plan for SMARCA4-dTTs. platinum-based chemotherapy, targeted therapy, a

SUBMITTER: Yang X 

PROVIDER: S-EPMC12688552 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature